Numient

RSS

levodopa / carbidopa

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Numient has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 09/08/2018

Authorisation details

Product details
Name
Numient
Agency product number
EMEA/H/C/002611
Active substance
  • levodopa
  • carbidopa
International non-proprietary name (INN) or common name
  • levodopa
  • carbidopa
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BA02
Publication details
Marketing-authorisation holder
Amneal Pharma Europe Ltd
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
19/11/2015
Contact address
70 Sir John Rogerson’s Quay
Dublin 2
Ireland

Product information

03/08/2018 Numient - EMEA/H/C/002611 - T/0005

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Symptomatic treatment of adult patients with Parkinson’s disease

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating